ALK Announces Posting Of Briefing Documents For FDA Advisory Committee Meeting On The Grass Sublingual AIT Tablet

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has posted briefing documents for the Allergenic Products Advisory Committee meeting on 12 December to review Merck’s Biologic License Application (BLA) for the investigational grass sublingual allergy immunotherapy (AIT) tablet (marketed in Europe as GRAZAX®).

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC